Abstract:Background & AimBile acids, as hydrophilicity/ hydrophobic molecules and natural ligands of bile acids receptors, are involved in the pathogenesis of liver injury and metabolic disorders. Cholestyramine acts as a bile acid chelating agent and is used to reduce cholesterol in clinic, but its hepatotoxicity and effects on metabolism are still unclear.MethodsApoE-/- mice were continuously administered with low fat diet with or without 2% cholestyramine 12 weeks to determine the hepatotoxicity and metabolic influences of cholestyramine on these mice. Serum transaminases, liver histological features and hepatic inflammatory markers expression were used to assess cholestyramine hepatotoxicity. Body weight, liver weight, serum lipids profile and liver lipid metabolism related genes expression were used to evaluate effects of cholestyramine on metabolism. Differences of endogenous bile acids composition, bile acids metabolism related genes and intestinal flora structure between groups were also analyzed by an ultraperformance liquid chromatography coupled to tandem mass spectrometry system, quantitative real time PCR and 16S rDNA sequencing.ResultsAfter 12 weeks of dietary intervention, although cholestyramine decreased ApoE-/- mice serum cholesterol level, it significantly increased the body and liver weight of these mice, and caused severe liver injury: increased serum transaminases levels, promoted liver vesicular steatosis and inflammatory cells infiltration, and enhanced the expression of lipid synthesis gene: FASN and inflammatory markers genes: TNF-α 、MCP-1、F4/80 and CD68. Moreover, cholestyramine administration caused hydrophobic transformation of bile acids pool and severe gut dysbiosis, which were characterized by decreased hydrophilic bile acids: muricholic acid (MCA) and ursodeoxycholic acid (UDCA), and increased abundance of potential pathogenic bacteria: s_Bacteroide_vulgatus.ConclusionThis study revealed that cholestyramine had the ability to induce severe liver injury and metabolic disorders. These effects might be attributed to inducing hydrophobic transformation of bile acids pool and gut dysbiosis by cholestyramine. Furthermore, our study provided a warning of hepatotoxicity and metabolic disorders for clinical application of cholestyramine, and suggested that cholestyramine was not a good scavenging tool to study the role of bile acids alternations in diseases progression.

Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice

Metabolomics and Lipidomics Reveal the Effect of Hepatic Vps33b Deficiency on Bile Acids and Lipids Metabolism

Hepatic Tmem30a Deficiency Causes Intrahepatic Cholestasis by Impairing Expression and Localization of Bile Salt Transporters.

Bile acid-gut microbiota imbalance in cholestasis and its long-term effect in mice

Cholestyramine Administration Induces Gut Dysbiosis and Severe Liver Injury in ApoE-/- Mice

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Novel Missense Mutation in VPS33B is Associated with Isolated Low Gamma-Glutamyltransferase Cholestasis: Attenuated, Incomplete Phenotype of Arthrogryposis, Renal Dysfunction, and Cholestasis Syndrome.

Conditional loss of geranylgeranyl diphosphate synthase alleviates acute obstructive cholestatic liver injury by regulating hepatic bile acid metabolism

Gut microbiota depletion aggravates bile acid-induced liver pathology in mice with a human-like bile acid composition

Vacuolar Protein Sorting 33B is a Tumor Suppressor in Hepatocarcinogenesis.

Deficiency of cholesterol 7α‐hydroxylase in bile acid synthesis exacerbates alcohol‐induced liver injury in mice

Cholestasis impairs hepatic lipid storage via AMPK and CREB signaling in hepatitis B virus surface protein transgenic mice

The contribution of small heterodimer partner to the occurrence and progression of cholestatic liver injury

Cholestatic insult triggers alcohol-associated hepatitis in mice

Gallbladder dysfunction caused by MYPT1 ablation triggers cholestasis-induced hepatic fibrosis in mice

Elucidating the hepatoprotective mechanisms of cholic acid against CCl 4 -Induced acute liver injury: A transcriptomic and metabolomic study

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

Reversal of hepatic accumulation of nordeoxycholic acid underlines the beneficial effects of cholestyramine on alcohol-associated liver disease in mice

PGC‐1α is downregulated in a mouse model of obstructive cholestasis but not in a model of liver fibrosis

Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal

Deficiency of Cystathionine Gamma-Lyase and Hepatic Cholesterol Accumulation During Mouse Fatty Liver Development